Evidence for a cystic fibrosis enteropathy

PLoS ONE

Volumn 10, Issue 10, 2015, Pages

  Adriaanse, Marlou P M ^a   Van Der Sande, Linda J T M ^a   Van Den Neucker, Anita M ^a   Menheere, Paul P C A ^b   Dompeling, Edward ^b   Buurman, Wim A ^b   Vreugdenhil, Anita C E ^a  

^a MAASTRICHT UNIVERSITY   (Netherlands)

^b MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

CALGRANULIN; FATTY ACID BINDING PROTEIN 2; PROTON PUMP INHIBITOR; FABP2 PROTEIN, HUMAN; FATTY ACID BINDING PROTEIN;

ADULT; ARTICLE; CELL DAMAGE; CHILD; COMPARATIVE STUDY; CONTROLLED STUDY; CYSTIC FIBROSIS; DIABETES MELLITUS; DISEASE ASSOCIATION; DRUG USE; ENTERITIS; ENTEROPATHY; FEMALE; FORCED EXPIRATORY VOLUME; FORCED VITAL CAPACITY; HUMAN; INTESTINE CELL; LUNG DISEASE; MAJOR CLINICAL STUDY; MALE; MORBIDITY; NUTRITIONAL STATUS; PANCREAS EXOCRINE INSUFFICIENCY; PREDICTIVE VALUE; PROTEIN BLOOD LEVEL; PROTEIN LOCALIZATION; RETROSPECTIVE STUDY; ADOLESCENT; AGED; BLOOD; CHEMISTRY; COMPLICATION; FECES; INFANT; INFLAMMATION; METABOLISM; MIDDLE AGED; PATHOLOGY; PRESCHOOL CHILD; VERY ELDERLY; YOUNG ADULT;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CHILD; CHILD, PRESCHOOL; CYSTIC FIBROSIS; FATTY ACID-BINDING PROTEINS; FECES; FEMALE; HUMANS; INFANT; INFLAMMATION; INTESTINAL DISEASES; LEUKOCYTE L1 ANTIGEN COMPLEX; MALE; MIDDLE AGED; NUTRITIONAL STATUS; YOUNG ADULT;

EID: 84949266495     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0138062     Document Type: Article

References (60)

1. Scaparrotta A, Di Pillo S, Attanasi M, Consilvio NP, Cingolani A, Rapino D, et al. Growth failure in children with cystic fibrosis. Journal of pediatric endocrinology & metabolism: JPEM 2012; 25:393-405. PMID: 22876530
2. Morison S, Dodge JA, Cole TJ, Lewis PA, Coles EC, Geddes D, et al. Height and weight in cystic fibrosis: a cross sectional study. UK Cystic Fibrosis Survey Management Committee. Archives of disease in childhood 1997; 77:497-500. PMID: 9496182
3. Corey M, McLaughlin FJ, Williams M, Levison H. A comparison of survival, growth, and pulmonary function in patients with cystic fibrosis in Boston and Toronto. Journal of clinical epidemiology 1988; 41:583-91. PMID: 3260274
4. Pencharz PB, Durie PR. Pathogenesis of malnutrition in cystic fibrosis, and its treatment. Clin Nutr 2000; 19:387-94. PMID: 11104588
5. Werlin SL, Benuri-Silbiger I, Kerem E, Adler SN, Goldin E, Zimmerman J, et al. Evidence of intestinal inflammation in patients with cystic fibrosis. Journal of pediatric gastroenterology and nutrition 2010; 51:304-8. doi: 10.1097/MPG.0b013e3181d1b013 PMID: 20512061
6. Steinkamp G, Wiedemann B. Relationship between nutritional status and lung function in cystic fibrosis: cross sectional and longitudinal analyses from the German CF quality assurance (CFQA) project. Thorax 2002; 57:596-601. PMID: 12096202
7. Sharma R, Florea VG, Bolger AP, Doehner W, Florea ND, Coats AJ, et al. Wasting as an independent predictor of mortality in patients with cystic fibrosis. Thorax 2001; 56:746-50. PMID: 11562511
8. Hendriks HJ, van Kreel B, Forget PP. Effects of therapy with lansoprazole on intestinal permeability and inflammation in young cystic fibrosis patients. Journal of pediatric gastroenterology and nutrition 2001; 33:260-5. PMID: 11593119
9. Madan JC, Koestler DC, Stanton BA, Davidson L, Moulton LA, Housman ML, et al. Serial analysis of the gut and respiratory microbiome in cystic fibrosis in infancy: interaction between intestinal and respiratory tracts and impact of nutritional exposures. mBio 2012; 3. doi: 10.1128/mBio.00251-12 PMID: 22911969
10. Dominguez JA, Vithayathil PJ, Khailova L, Lawrance CP, Samocha AJ, Jung E, et al. Epidermal growth factor improves survival and prevents intestinal injury in a murine model of pseudomonas aeruginosa pneumonia. Shock 2011; 36:381-9. doi: 10.1097/SHK.0b013e31822793c4 PMID: 21701422
11. Briars GL, Dean TP, Murphy JL, Rolles CJ, Warner JO. Faecal interleukin-8 and tumour necrosis factor-alpha concentrations in cystic fibrosis. Archives of disease in childhood 1995; 73:74-6. PMID: 7639556
12. Bruzzese E, Raia V, Gaudiello G, Polito G, Buccigrossi V, Formicola V, et al. Intestinal inflammation is a frequent feature of cystic fibrosis and is reduced by probiotic administration. Alimentary pharmacology & therapeutics 2004; 20:813-9. PMID: 15379842
13. Lisowska A, Madry E, Pogorzelski A, Szydlowski J, Radzikowski A, Walkowiak J. Small intestine bacterial overgrowth does not correspond to intestinal inflammation in cystic fibrosis. Scand J Clin Lab Invest 2010; 70:322-6. doi: 10.3109/00365513.2010.486869 PMID: 20560844
14. Norkina O, Kaur S, Ziemer D, De Lisle RC. Inflammation of the cystic fibrosis mouse small intestine. American journal of physiology Gastrointestinal and liver physiology 2004; 286:G1032-41. PMID: 14739145
15. Raia V, Maiuri L, de Ritis G, de Vizia B, Vacca L, Conte R, et al. Evidence of chronic inflammation in morphologically normal small intestine of cystic fibrosis patients. Pediatric research 2000; 47:344-50. PMID: 10709733
16. Smyth RL, Croft NM, O'Hea U, Marshall TG, Ferguson A. Intestinal inflammation in cystic fibrosis. Archives of disease in childhood 2000; 82:394-9. PMID: 10799435
17. Croft NM, Marshall TG, Ferguson A. Gut inflammation in children with cystic fibrosis on high-dose enzyme supplements. Lancet 1995; 346:1265-7. PMID: 7475719
18. Bensalem N, Ventura AP, Vallee B, Lipecka J, Tondelier D, Davezac N, et al. Down-regulation of the anti-inflammatory protein annexin A1 in cystic fibrosis knock-out mice and patients. Molecular & cellular proteomics: MCP 2005; 4:1591-601. PMID: 16014420
19. Pezzilli R, Barassi A, Morselli-Labate AM, Fantini L, Tomassetti P, Campana D, et al. Fecal calprotectin and elastase 1 determinations in patients with pancreatic diseases: a possible link between pancreatic insufficiency and intestinal inflammation. Journal of gastroenterology 2007; 42:754-60. PMID: 17876545
20. Lisowska A, Wojtowicz J, Walkowiak J. Small intestine bacterial overgrowth is frequent in cystic fibrosis: combined hydrogen and methane measurements are required for its detection. Acta Biochim Pol 2009; 56:631-4. PMID: 19997657
21. Sbarbati A, Bertini M, Catassi C, Gagliardini R, Osculati F. Ultrastructural lesions in the small bowel of patients with cystic fibrosis. Pediatric research 1998; 43:234-9. PMID: 9475290
22. Gelfond D, Ma C, Semler J, Borowitz D. Intestinal pH and gastrointestinal transit profiles in cystic fibrosis patients measured by wireless motility capsule. Digestive diseases and sciences 2013; 58:2275-81. doi: 10.1007/s10620-012-2209-1 PMID: 22592630
23. De Lisle RC. Pass the bicarb: the importance of HCO3-for mucin release. The Journal of clinical investigation 2009; 119:2535-7. doi: 10.1172/JCI40598 PMID: 19726878
24. van Elburg RM, Uil JJ, van Aalderen WM, Mulder CJ, Heymans HS. Intestinal permeability in exocrine pancreatic insufficiency due to cystic fibrosis or chronic pancreatitis. Pediatric research 1996; 39:985-91. PMID: 8725259
25. Levy E, Menard D, Delvin E, Montoudis A, Beaulieu JF, Mailhot G, et al. Localization, function and regulation of the two intestinal fatty acid-binding protein types. Histochemistry and cell biology 2009; 132:351-67. doi: 10.1007/s00418-009-0608-y PMID: 19499240
26. Derikx JP, Vreugdenhil AC, Van den Neucker AM, Grootjans J, van Bijnen AA, Damoiseaux JG, et al. A pilot study on the noninvasive evaluation of intestinal damage in celiac disease using I-FABP and LFABP. Journal of clinical gastroenterology 2009; 43:727-33. doi: 10.1097/MCG.0b013e31819194b0 PMID: 19359998
27. Pelsers MM, Namiot Z, Kisielewski W, Namiot A, Januszkiewicz M, Hermens WT, et al. Intestinal-type and liver-type fatty acid-binding protein in the intestine. Tissue distribution and clinical utility. Clinical biochemistry 2003; 36:529-35. PMID: 14563446
28. Schellekens DH, Grootjans J, Dello SA, van Bijnen AA, van Dam RM, Dejong CH, et al. Plasma intestinal fatty acid-binding protein levels correlate with morphologic epithelial intestinal damage in a human translational ischemia-reperfusion model. Journal of clinical gastroenterology 2014; 48:253-60. doi: 10.1097/MCG.0b013e3182a87e3e PMID: 24100750
29. Yui S, Nakatani Y, Mikami M. Calprotectin (S100A8/S100A9), an inflammatory protein complex from neutrophils with a broad apoptosis-inducing activity. Biological & pharmaceutical bulletin 2003; 26:753-60. PMID: 12808281
30. Sinaasappel M, Stern M, Littlewood J, Wolfe S, Steinkamp G, Heijerman HG, et al. Nutrition in patients with cystic fibrosis: a European Consensus. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2002; 1:51-75.
31. Borowitz D, Baker RD, Stallings V. Consensus report on nutrition for pediatric patients with cystic fibrosis. Journal of pediatric gastroenterology and nutrition 2002; 35:246-59. PMID: 12352509
32. Walkowiak J, Nousia-Arvanitakis S, Henker J, Stern M, Sinaasappel M, Dodge JA. Indirect pancreatic function tests in children. Journal of pediatric gastroenterology and nutrition 2005; 40:107-14. PMID: 15699676
33. Kerem E, Conway S, Elborn S, Heijerman H, Consensus C. Standards of care for patients with cystic fibrosis: a European consensus. Journal of cystic fibrosis: official journal of the European Cystic Fibrosis Society 2005; 4:7-26.
34. Hoffmanova I, Sanchez D, Habova V, Andel M, Tuckova L, Tlaskalova-Hogenova H. Serological markers of enterocyte damage and apoptosis in patients with celiac disease, autoimmune diabetes mellitus and diabetes mellitus type 2. Physiological research / Academia Scientiarum Bohemoslovaca 2014. PMID: 25470519
35. Verdam FJ, Greve JW, Roosta S, van Eijk H, Bouvy N, Buurman WA, et al. Small intestinal alterations in severely obese hyperglycemic subjects. The Journal of clinical endocrinology and metabolism 2011; 96:E379-83. doi: 10.1210/jc.2010-1333 PMID: 21084402
36. Sun X, Olivier AK, Yi Y, Pope CE, Hayden HS, Liang B, et al. Gastrointestinal pathology in juvenile and adult CFTR-knockout ferrets. The American journal of pathology 2014; 184:1309-22. doi: 10.1016/j. ajpath.2014.01.035 PMID: 24637292
37. De Lisle RC, Mueller R, Boyd M. Impaired mucosal barrier function in the small intestine of the cystic fibrosis mouse. Journal of pediatric gastroenterology and nutrition 2011; 53:371-9. doi: 10.1097/MPG. 0b013e318219c397 PMID: 21970994
38. Vreugdenhil AC, Wolters VM, Adriaanse MP, Van den Neucker AM, van Bijnen AA, Houwen R, et al. Additional value of serum I-FABP levels for evaluating celiac disease activity in children. Scandinavian journal of gastroenterology 2011; 46:1435-41. doi: 10.3109/00365521.2011.627447 PMID: 22029621
39. Adriaanse MP, Tack GJ, Passos VL, Damoiseaux JG, Schreurs MW, van Wijck K, et al. Serum I-FABP as marker for enterocyte damage in coeliac disease and its relation to villous atrophy and circulating autoantibodies. Alimentary pharmacology & therapeutics 2013. doi: 10.1111/apt.12194 PMID: 23289539
40. Kerem E, Viviani L, Zolin A, Macneill S, Hatziagorou E, Ellemunter H, et al. Factors associated with FEV1 decline in cystic fibrosis: analysis of the data of the ECFS Patient Registry. The European respiratory journal 2013. doi: 10.1183/09031936.00166412 PMID: 23598952
41. Rumman N, Sultan M, El-Chammas K, Goh V, Salzman N, Quintero D, et al. Calprotectin in cystic fibrosis. BMC pediatrics 2014; 14:133. doi: 10.1186/1471-2431-14-133 PMID: 24885444
42. Lloyd-Still JD, Beno DW, Kimura RM. Cystic fibrosis colonopathy. Current gastroenterology reports 1999; 1:231-7. PMID: 10980955
43. Klingberg E, Carlsten H, Hilme E, Hedberg M, Forsblad-d'Elia H. Calprotectin in ankylosing spondylitis - frequently elevated in feces, but normal in serum. Scandinavian journal of gastroenterology 2012; 47:435-44. doi: 10.3109/00365521.2011.648953 PMID: 22229862
44. Poullis A, Foster R, Mendall MA, Shreeve D, Wiener K. Proton pump inhibitors are associated with elevation of faecal calprotectin and may affect specificity. European journal of gastroenterology & hepatology 2003; 15:573-4; author reply 4. PMID: 12702920
45. De Boeck K, Weren M, Proesmans M, Kerem E. Pancreatitis among patients with cystic fibrosis: correlation with pancreatic status and genotype. Pediatrics 2005; 115:e463-9. PMID: 15772171
46. Gray RD, MacGregor G, Noble D, Imrie M, Dewar M, Boyd AC, et al. Sputum proteomics in inflammatory and suppurative respiratory diseases. American journal of respiratory and critical care medicine 2008; 178:444-52. doi: 10.1164/rccm.200703-409OC PMID: 18565957
47. Bruzzese E, Raia V, Spagnuolo MI, Volpicelli M, De Marco G, Maiuri L, et al. Effect of Lactobacillus GG supplementation on pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Clinical nutrition 2007; 26:322-8. PMID: 17360077
48. Norkina O, Burnett TG, De Lisle RC. Bacterial overgrowth in the cystic fibrosis transmembrane conductance regulator null mouse small intestine. Infection and immunity 2004; 72:6040-9. PMID: 15385508
49. Sly PD, Brennan S, Gangell C, de Klerk N, Murray C, Mott L, et al. Lung disease at diagnosis in infants with cystic fibrosis detected by newborn screening. American journal of respiratory and critical care medicine 2009; 180:146-52. doi: 10.1164/rccm.200901-0069OC PMID: 19372250
50. Walkowiak J, Blask-Osipa A, Lisowska A, Oralewska B, Pogorzelski A, Cichy W, et al. Cystic fibrosis is a risk factor for celiac disease. Acta Biochim Pol 2010; 57:115-8. PMID: 20300660
51. Lloyd-Still JD. Cystic fibrosis, Crohn's disease, biliary abnormalities, and cancer. Journal of pediatric gastroenterology and nutrition 1990; 11:434-7. PMID: 2132081
52. Smyth RL, van Velzen D, Smyth AR, Lloyd DA, Heaf DP. Strictures of ascending colon in cystic fibrosis and high-strength pancreatic enzymes. Lancet 1994; 343:85-6. PMID: 7903780
53. Gosden CM, Gosden JR. Fetal abnormalities in cystic fibrosis suggest a deficiency in proteolysis of cholecystokinin. Lancet 1984; 2:541-6. PMID: 6147603
54. Yu H, Nasr SZ, Deretic V. Innate lung defenses and compromised Pseudomonas aeruginosa clearance in the malnourished mouse model of respiratory infections in cystic fibrosis. Infection and immunity 2000; 68:2142-7. PMID: 10722612
55. Weiss B, Bujanover Y, Yahav Y, Vilozni D, Fireman E, Efrati O. Probiotic supplementation affects pulmonary exacerbations in patients with cystic fibrosis: a pilot study. Pediatric pulmonology 2010; 45:536-40. doi: 10.1002/ppul.21138 PMID: 20503277
56. Rutten EP, Lenaerts K, Buurman WA, Wouters EF. Disturbed intestinal integrity in patients with COPD; effects of activities of daily living. Chest 2013. doi: 10.1378/chest.13-0584 PMID: 23928850
57. Sandek A, Bauditz J, Swidsinski A, Buhner S, Weber-Eibel J, von Haehling S, et al. Altered intestinal function in patients with chronic heart failure. Journal of the American College of Cardiology 2007; 50:1561-9. PMID: 17936155
58. Chmiel JF, Berger M, Konstan MW. The role of inflammation in the pathophysiology of CF lung disease. Clinical reviews in allergy & immunology 2002; 23:5-27. PMID: 12162106
59. Balfour-Lynn IM, Dinwiddie R. Role of corticosteroids in cystic fibrosis lung disease. Journal of the Royal Society of Medicine 1996; 89 Suppl 27:8-13. PMID: 8778452
60. Goss CH, Ratjen F. Update in cystic fibrosis 2012. Am J Respir Crit Care 2013; 187:915-9